nach oben

Erschienen in:

01.06.2018 | Clinical study

Potential safety signals with biologic use identified

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Potential safety signals associated with the use of biologic agents including infliximab and rituximab have been identified and require further investigation, say authors of a disproportionality analysis of adverse events reported to the US FDA Adverse Event Reporting System (FAERS), published in BioDrugs. …

progressive multifocal leukoencephalopathy

Araujo AGS, et al. Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). BioDrugs : 5 Jun 2018. Available from: URL: http://doi.org/10.1007/s40259-018-0285-2

Titel: Potential safety signals with biologic use identified
Publikationsdatum: 01.06.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-47825-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Hydroxychloroquine

Haloperidol

Carbamazepine

Japanese encephalitis vaccine has favourable safety profile

Etanercept/isoniazid

Dabrafenib/trametinib